Skip to main content

Table 3 Results from the five regression models

From: Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation

Variable description

Model 1

Model 2

Model 3

Model 4

Model 5

N

184

183

182

182

182

Employed at survey

Yes

Yes

Yes

Yes

Yes

Constant

0.333***

0.701***

0.812**

0.955***

0.962***

 

(3.85)

(3.70)

(3.20)

(3.79)

(3.71)

Employed before HDT-ASCT

0.448***

0.445***

0.436***

0.384***

0.373***

 

(4.83)

(4.70)

(4.62)

(4.09)

(4.00)

Female

 

−0.094

−0.066

−0.034

− 0.040

  

(−1.43)

(−1.00)

(− 0.52)

(0.60)

Married

 

−0.125

−0.168*

− 0.146*

−0.143*

  

(−1.69)

(−2.31)

(−2.05)

(−2.01)

Higher education

 

0.040

0.073

0.054

0.072

  

(0.63)

(1.20)

(0.90)

(1.18)

Age at survey

 

−0.005

−0.004

−0.005

−0.004

  

(−1.63)

(−1.36)

(−1.82)

(−1.15)

Body Mass Index

  

−0.005

−0.004

− 0.006

   

(−0.71)

(−0.57)

(− 0.91)

Heart disease

  

0.076

0.095

0.063

   

(0.66)

(0.83)

(0.55)

Second cancer

  

−0.444***

−0.410***

−0.474***

   

(−4.34)

(−4.09)

(−4.54)

Relapse

  

0.104

0.078

0.138

   

(1.30)

(0.98)

(1.65)

Chronic fatigue

   

−0.126*

−0.109

    

(−1.93)

(−1.65)

Anxiety

   

−0.176*

−0.192*

    

(−2.20)

(2.40)

Treatment lines

 One

    

(base outcome)

 Two

    

0.009

     

(0.13)

 More than two

    

−0.168

     

(−1.57)

Lymphoma type

     

 Hodgkin

    

(base outcome)

 Aggressive

    

−0.008

     

(0.09)

 Indolent

    

−0.143

     

(−1.12)

Variation in model explained (%)

0.11

0.15

0.23

0.28

0.30

  1. Statistics: Each coefficient shows how the probability of employment at survey relates to the various covariates (* p < 0.05; ** p < 0.01; *** p < 0.001; t-values in parentheses).
  2. Employment before treatment, conditioned on being employed at onset, stays significant throughout all five regression models (* p < 0.05; ** p < 0.01; *** p < 0.001; t-values in parentheses). HDT-ASCT = high-dose chemotherapy with autologous stem-cell transplantation.